UNC Lineberger faculty and trainees will be presenting their research findings and sharing their insights at education sessions during the American Association for Cancer Research’s annual meeting in Orlando, Fla., April 14-19.
This year’s meeting, which will focus on Advancing the Frontiers of Cancer Science and Medicine, historically draws together some 20,000 attendees from around the world and features presentations on the latest advances in basic, translational, and clinical cancer research.
The UNC Lineberger presentations include:
Saturday, April 15, 2023
Education Session
ED041 – Tumor-infiltrating B Cells and Tertiary Lymphoid Structures: Mechanistic Insights and Therapeutic Opportunities
12:30 – 2:00 PM Tangerine Ballroom 1 (WF1) – Convention Center
1:00 – 1:20 PM – Regulatory B cells in cancer
Yuliya Pylayeva-Gupta, PhD
Sunday, April 16, 2023
Opening Ceremony
8:00 – 9:30 AM W Hall A2-3 – Convention Center
AACR Academy Fellows announced: Chuck Perou, PhD
Major Symposium
SY16 – B Cell Responses and Tertiary Lymphoid Structures in Cancer
1:00 – 2:30 PM Tangerine Ballroom 1 (WF1) – Convention Center
Chaired by Yuliya Pylayeva-Gupta, PhD
1:05 – 1:25 PM Determinants of B cell function in cancer
Yuliya Pylayeva-Gupta, PhD
Poster Session
PO.CL01.01 – Biomarkers of Therapeutic Benefit 1
1:30 – 5:00 PM Section 39
Zachary Schrank
PO.CL09.03 – Precision Molecular Subtyping and Therapeutic Development
1:30 – 5:00 PM Section 43
1075 / 19 – Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer
Andrew Michael Waters, PhD
PO.IM02.02 – Cancer-associated Inflammation and Microbiome
1:30 – 5:00 PM Section 22
656 / 29 – Suppression of pyruvate carboxylase drives tumor microenvironment immunosuppression
Michael F. Coleman, PhD
Special Session
4:00 – 5:00 PM Room W330 – Convention Center
Chairperson: Patricia Spears
Monday, April 17, 2023
Poster Session
PO.PS01.08 – Cancer Disparities 2
9:00 AM – 12:30 PM Section 27
Mya L. Roberson, PhD
PO.CL01.07 – Diagnostic and Prognostic Biomarkers 2
9:00 AM – 12:30 PM Section 41
2217 / 27 – Novel risk stratification utilizing NanoString for HPV+ head and neck cancer patients
Sulgi Kim
PO.IM01.08 – Immunomodulatory Agents and Interventions 1
9:00 AM – 12:30 PM Section 23
Mostafa Yazdimamaghani, PhD
PO.TB02.01 – Carcinogenesis and Mutagenesis
9:00 AM – 12:30 PM Section 1
Jason Tasoulas, MD, DMD
PO.TB11.04 – Metabolic Influences on the Tumor Microenvironment
9:00 AM – 12:30 PM Section 3
1267 / 18 – Suppression of pyruvate carboxylase drives PDL1 expression in mouse models of TNBC
Numair Attaar
Major Symposium
SY42 – Molecular Mechanisms of KRAS Pathway Inhibitors
12:30 – 2:00 PM Valencia D – Convention Center
1:00 PM – 1:20 PM Targeting KRAS for pancreatic cancer treatment
Channing J. Der, PhD
Poster Session
PO.PR01.03 – Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship
1:30 – 5:00 PM Section 28
Ximena Minerva Bustamante-Marin, PhD
Tuesday, April 18, 2023
Plenary
PL04 – Embracing Immune Ecosystems
8:00 – 10:00 AM W Hall A2-3 – Convention Center
9:11 – 9:33 AM CAR-T cells: Next generation
Gianpietro Dotti, PhD
Poster Session
PO.ET06.03 – Identification of Molecular Targets 1
9:00 AM – 12:30 PM Section 17
3925 / 13 – JunB regulates expression of HPV genes in head and neck cancer
Hina Rehmani, PhD
PO.PR02.01 – Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention
9:00 AM – 12:30 PM Section 30
Elaine M. Glenny, PhD
Major Symposium
DC12 – Project Site Selector: Navigating Oncology Drug Development through Troubled Waters
10:15 – 11:45 AM Room W315 – Convention Center
Speaker: Carrie Lee, MD, MPH
Poster Session
PO.CL06.01 – Community-based Research and Biobanking Research
1:30 – 5:00 PM Section 39
Marjory Charlot, MD, MPH, MSc
Marjory Charlot, MD, MPH, MSc
PO.CTP01.01 – Phase I and First-in-Human Clinical Trials in Progress
1:30 – 5:00 PM Section 46
Yara Abdou, MD
PO.ET05.02 – Anticancer Approaches Targeting Signal Transduction Pathways
1:30 – 5:00 PM Section 13
4867 / 10 – Effect of FGFR3 activity on Nectin-4 expression in urothelial carcinoma
Sean Clark-Garvey, MD
PO.IM01.10 – Inflammation and Immunity in the Tumor Microenvironment
1:30 – 5:00 PM Section 23
5156 / 28 – The mutagenic effects of APOBEC3A and APOBEC3B in urothelial carcinoma
Michael S. Sturdivant
PO.MCB09.03 – Role of Mitochondria and Signaling Pathways in Cancer
1:30 – 5:00 PM Section 12
Jonathan M. DeLiberty
Major Symposium
DC14 – Liquid Biopsies for Curative-Intent Solid Tumor Drug Development
2:30 – 4:00 PM Room W315 – Convention Center
Panelist: Patricia Spears
Mini Symposium
MS.MCB07.01 – Gene Regulation and Transcription Factors in Cancer
2:30 – 4:30 PM Room W311 A-D – Convention Center
5754 – Determining the regulatory logic of breast cancer cells using single-cell multi-omics
Hector L. Franco, PhD
MS.CL09.01 – The Next Wave of Precision Oncology: New Drugs, Databases, and Analytics to Refine Care
2:30 – 4:00 PM Room W414 – Convention Center
Adam C. Palmer, PhD
Wednesday, April 19, 2023
LBPO.IM03 – Late-Breaking Research: Immunology 3
9:00 AM – 12:30 PM Section 36
LB350 / 18 – Novel mouse model to study HPV associated pathologies
Xue Li, PhD
Poster Session
PO.CL07.08 – Immune Monitoring and Responses to Therapy
9:00 AM – 12:30 PM Section 39
Wolfgang Beckabir
PO.ET06.05 – Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes
9:00 AM – 12:30 PM Section 16
Aditi Kothari
PO.ET09.05 – Epigenetics
9:00 AM – 12:30 PM Section 20
6281 / 19 – OTX-015 inhibits proliferation and migration in ARID1A-mutated bladder cancer
Ryan M. Kemper
PO.IM01.05 – Immune Checkpoints
9:00 AM – 12:30 PM Section 23
6362 / 6 – Overcoming resistance to immunotherapy due to loss of antigen presentation
Brian C. Miller, MD, PhD
SY36 – Global Cancer Burden: Challenges and Opportunities for Innovation
10:15 – 11:45 AM Room W311 E-H – Convention Center
Chemtai Mungo, MD, MPH